Preclinical/Co-Clinical Section

临床前/临床联合部分

基本信息

批准号：
10251355
负责人：
Cathleen M Lutz
金额：
$ 15.12万
依托单位：
JACKSON LABORATORY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-01 至 2025-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10251355
关键词：
Address Adoption Animal Model Benchmarking Biology Biomedical Research CLIA certified Client Clinical Clinical Data Clinical Trials Collaborations Collection Communities Data Disease model Drug Kinetics Ensure Faculty Fee-for-Service Plans Felis catus Future Genetic Genomic medicine Goals Grant Health Hospitals Human Human Genetics Individual Industry Industry Collaboration Infrastructure Knowledge Laboratories Lead Medical center Modality Modeling Mouse Strains Mus Patients Pharmacology Phenotype Plug-in Positioning Attribute Preclinical Testing Production Rare Diseases Recommendation Research Research Personnel Resources Role Sampling Series Services Testing The Jackson Laboratory Therapeutic Toxicology Translations Treatment Efficacy Validation Work base clinical application clinical phenotype clinical practice data exchange drug testing experience genomic data human disease in vivo model development operation pre-clinical precision genetics repository somatic cell gene editing tool

Address Adoption Animal Model Benchmarking Biology Biomedical Research CLIA certified Client Clinical Clinical Data Clinical Trials Collaborations Collection Communities Data Disease model Drug Kinetics Ensure Faculty Fee-for-Service Plans Felis catus Future Genetic Genomic medicine Goals Grant Health Hospitals Human Human Genetics Individual Industry Industry Collaboration Infrastructure Knowledge Laboratories Lead Medical center Modality Modeling Mouse Strains Mus Patients Pharmacology Phenotype Plug-in Positioning Attribute Preclinical Testing Production Rare Diseases Recommendation Research Research Personnel Resources Role Sampling Series Services Testing The Jackson Laboratory Therapeutic Toxicology Translations Treatment Efficacy Validation Work base clinical application clinical phenotype clinical practice data exchange drug testing experience genomic data human disease in vivo model development operation pre-clinical precision genetics repository somatic cell gene editing tool

展开

项目摘要

PROJECT SUMMARY PRECLINICAL/CO-CLINICAL CORE The Jackson Laboratory (JAX) and The Jackson Laboratory Center for Precision Genetics (JCPG) occupy a unique niche within the global biomedical research community. Although we do not see patients, many of these individuals have benefited from our stewardship of the thousands of different mouse strains that JAX provides for use in human disease research. And it is not just our mice; our faculty researchers, with deep expertise in genetics and mammalian biology, collaborate directly with investigators at hospitals, medical centers and an array of other clinically oriented partners worldwide. Thus, the JCPG will operate using a “hub and spokes” concept where the JCPG forms part of a mammalian disease model “hub” that integrates a variety of JAX resources to establish an array of collaborative “spokes” with a variety of partners to co-produce precise preclinical disease models. The Preclinical/Co-clinical core of the JCPG will work with expert clinical, patient, research and industry collaborators to facilitate optimal creation and application of existing and nominated projects. Together with the JCPG Coordination Core, the Preclinical/Co-clinical Core and the Steering Committee will apply a series of benchmark standards to work toward the eventual goal of translation into clinical practice. Ultimately, we will further extend our impact by providing a more advanced Fee for Service approach to broaden community access to JAX resources. To meet current goals of the JCPG and to refine and expand its future operation, the Preclinical/Co-clinical Core will: 1) Solicit, evaluate and prioritize new preclinical/co-clinical project requests and provide recommendations to the Steering Committee for adoption by the JCPG. 2) Advance new models through the production-like pipelines, with characterization and drug testing so they can more tangibly inform future clinical applications. 3) Continue to develop and expand existing JAX infrastructure to facilitate access to clinical data and samples, supporting data exchange between mouse information and patient data.

项目摘要临床前/共同链式核心杰克逊实验室（JAX）和杰克逊实验室精密遗传学中心（JCPG）占据全球生物医学研究界的独特利基市场。尽管我们看不到病人，但很多这些人受益于我们对数千种不同老鼠菌株的管理规定用于人类疾病研究。这不仅是我们的老鼠；我们的教师研究人员，深遗传学和哺乳动物生物学方面的专业知识直接与医院的研究人员合作全世界的中心和许多其他面向临床的合作伙伴。那就是JCPG将使用“枢纽和说话”概念，其中JCPG构成了哺乳动物疾病模型“集线器”的一部分 JAX资源的建立一系列与各种合作伙伴共同生产精度的合作“发言” 临床前疾病模型。 JCPG的临床前/共同链式核心将与专家临床，患者一起工作研究和行业合作者促进现有和提名的最佳创建和应用项目。与JCPG协调核心，临床前/共同链式核心和转向委员会将采用一系列基准标准来努力将翻译成的活动目标临床实践。最终，我们将通过提供更高的服务费来进一步扩大影响扩大社区访问JAX资源的方法。满足JCPG的当前目标并完善并扩大其未来的运营，临床前/共同链式核心将：1）征求，评估和优先级临床前/共同链接项目请求，并向指导委员会提出建议 JCPG。 2）通过类似生产的管道推进新模型，并具有表征和药物进行测试，以便他们可以更明显地为未来的临床应用提供信息。 3）继续发展和扩展现有的JAX基础架构，以促进访问临床数据和样本，支持数据交换鼠标信息和患者数据。